NCT07261228

Brief Summary

The goal of this observational study is to learn about the carbon footprint produced from diagnostic upper GI endoscopy in patients with dyspepsia and therapeutic upper GI endoscopy in patients with non-variceal upper GI bleeding. The main question it aims to answer is: • How much carbon footprint is generated from upper GI endoscopy Participants are already receiving diagnostic and therapeutic upper GI endoscopy as part of their regular medical care for dyspepsia and non-variceal upper GI bleeding, respectively. The carbon footprint generated from this treatment process is examined.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
75

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2025

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2025

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

November 21, 2025

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 3, 2025

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2025

Completed
Last Updated

December 3, 2025

Status Verified

June 1, 2025

Enrollment Period

3 months

First QC Date

November 21, 2025

Last Update Submit

November 21, 2025

Conditions

Keywords

Carbon footprintUpper GI endoscopyEGDDyspepsiaNon-variceal upper gastrointestinal bleeding

Outcome Measures

Primary Outcomes (1)

  • To quantify the carbon footprint of diagnostic endoscopy for dyspepsia and therapeutic endoscopy for peptic ulcer bleeding

    The primary outcome is to calculate the carbon footprint produced from diagnostic upper GI endoscopy in dyspepsia patients and therapeutic upper GI endoscopy in peptic ulcer patients, focusing on the carbon footprint produced since the patient enter the endoscopy room until they leave the endoscopy room

    From enrollment to the time that patients leave the endoscopy room

Secondary Outcomes (3)

  • To compare carbon emissions between diagnostic and therapeutic upper GI endoscopy

    From enrollment to the time that patients leave the endoscopy room

  • To compare emissions across different hemostatic techniques (clips, argon plasma coagulation, bipolar probe), with or without epinephrine.

    From enrollment to the time that patients leave the endoscopy room

  • To evaluate procedural success rates of bleeding stoppage and adverse events (e.g., perforation, post-procedural sepsis) by different techniques

    From enrollment to 30 days after treatment

Study Arms (2)

Diagnostic upper GI endoscopy

Dyspepsia patient receiving diagnostic upper GI endoscopy

Therapeutic upper GI endoscopy

Non-variceal upper GI bleeding patient receiving therapeutic upper GI endoscopy

Eligibility Criteria

Age20 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Dyspepsia patients and non-variceal upper GI bleeding receiving upper GI endoscopy at King Chulalongkorn Memorial hospital and Sawanpracharak hospital, Thailand

You may qualify if:

  • Patients with dyspepsia or non-variceal upper GI bleeding
  • Age 20-80 years
  • Body mass index of 30 or less;
  • Receiving one of the following procedure during upper GI endoscopy:
  • For diagnostic endoscopy: Rapid urease test for H. pylori infection For therapeutic endoscopy: stop bleeding with either Argon plasma coagulation or Bipolar hemostasis probe or Hemostasis clip

You may not qualify if:

  • Platelet \< 50,000
  • INR \> 2.5
  • Pregnancy
  • History of allergy to IV sedative medication
  • Peptic ulcer grade IIc and III according to Forrest classification
  • Patient receiving inhalation anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

King Chulalongkorn Memorial Hospital

Bangkok, 10330, Thailand

RECRUITING

Sawanpracharak Hospital

Nakhon Sawan, 60000, Thailand

RECRUITING

MeSH Terms

Conditions

Dyspepsia

Condition Hierarchy (Ancestors)

Signs and Symptoms, DigestiveSigns and SymptomsPathological Conditions, Signs and Symptoms

Central Study Contacts

Ponthakorn Pichayanont, Doctor of Medicine

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assoc. Prof. Dr.

Study Record Dates

First Submitted

November 21, 2025

First Posted

December 3, 2025

Study Start

June 1, 2025

Primary Completion

August 31, 2025

Study Completion

December 31, 2025

Last Updated

December 3, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations